Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBITDA Margin: 2013-2025

Historic EBITDA Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -472.35%.

  • Ocular Therapeutix's EBITDA Margin fell 17414.00% to -472.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -449.66%, marking a year-over-year decrease of 21975.00%. This contributed to the annual value of -269.57% for FY2024, which is 12861.00% down from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's EBITDA Margin is -472.35%, which was up 6.01% from -502.57% recorded in Q2 2025.
  • Ocular Therapeutix's 5-year EBITDA Margin high stood at -127.41% for Q3 2023, and its period low was -597.47% during Q1 2025.
  • Its 3-year average for EBITDA Margin is -292.07%, with a median of -265.13% in 2024.
  • In the last 5 years, Ocular Therapeutix's EBITDA Margin soared by 96,719bps in 2021 and then slumped by 38,346bps in 2025.
  • Over the past 5 years, Ocular Therapeutix's EBITDA Margin (Quarterly) stood at -146.64% in 2021, then surged by 909bps to -137.56% in 2022, then spiked by 209bps to -135.46% in 2023, then tumbled by 16,061bps to -296.08% in 2024, then slumped by 17,414bps to -472.35% in 2025.
  • Its EBITDA Margin was -472.35% in Q3 2025, compared to -502.57% in Q2 2025 and -597.47% in Q1 2025.